RecruitingPHASE1, PHASE2NCT06185673
A Study to Evaluate the Safety and Clinical Activity of Intramuscular Doses of BB-301 Administered to Subjects With Oculopharyngeal Muscular Dystrophy With Dysphagia
Studying Oculopharyngeal muscular dystrophy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Benitec Biopharma, Inc.
- Principal Investigator
- Milan R. Amin, M.D.NYU Langone Health
- Intervention
- BB-301: Dose escalation phase 1b cohort 1(genetic)
- Enrollment
- 30 enrolled
- Eligibility
- 65 years · All sexes
- Timeline
- 2023 – 2040
Study locations (1)
- NYU Langone Health, New York, New York, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06185673 on ClinicalTrials.govOther trials for Oculopharyngeal muscular dystrophy
Additional recruiting or active studies for the same condition.